Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study

D. Bliuc*, T. Tran, T. van Geel, J. D. Adachi, C. Berger, J. van den Bergh, J. A. Eisman, P. Geusens, D. Goltzman, D. A. Hanley, R. G. Josse, S. Kaiser, C. S. Kovacs, L. Langsetmo, J. C. Prior, T. Nguyen, J. R. Center, CaMOS Res Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)817-828
Number of pages12
JournalOsteoporosis International
Volume30
Issue number4
DOIs
Publication statusPublished - Apr 2019

Keywords

  • Bisphosphonate
  • Fracture
  • Mortality risk
  • Osteoporosis
  • Prospective study
  • DELTA T-CELLS
  • SUBSEQUENT FRACTURE
  • BONE LOSS
  • OSTEOPOROTIC FRACTURE
  • ZOLEDRONIC ACID
  • HIP FRACTURE
  • WOMEN
  • MEN
  • PAMIDRONATE
  • EFFICACY

Cite this

Bliuc, D., Tran, T., van Geel, T., Adachi, J. D., Berger, C., van den Bergh, J., Eisman, J. A., Geusens, P., Goltzman, D., Hanley, D. A., Josse, R. G., Kaiser, S., Kovacs, C. S., Langsetmo, L., Prior, J. C., Nguyen, T., Center, J. R., & CaMOS Res Grp (2019). Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study. Osteoporosis International, 30(4), 817-828. https://doi.org/10.1007/s00198-018-4806-0